EUVIMEDEUVIMED entdecken
Open Access

Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer

Ana Lameirinhas, Paula Díez, Francisco J Hicke, Anna Ágreda-Roca, Sandra Torres-Ruiz, Paloma Sánchez-Serrano, Marta Tapia, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo, Ramón Martínez-Máñez, Pilar Eroles und 1 weitere

Biomaterials Research · 01.01.2026 · 30

DOI: 10.34133/bmr.0347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomaterials Research, online erschienen am 08.04.2026. Verfasst von Ana Lameirinhas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Institute INCLIVA, Breast Cancer Biology Research Group, Valencia, Spain. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Universitat Politècnica de València.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) remains a highly aggressive subtype with limited treatment options and poor prognosis. While most therapies target tumor cells, the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), plays a key role in tumor progression, therapy resistance, and immune suppression. We developed NP-FAP-DOX, a mesoporous silica nanoparticle-based nanodevice loaded with doxorubicin and functionalized with a fibroblast activation protein alpha (FAP-α) ligand peptide for selective binding to FAP-α-positive CAFs. FAP-α targeting ability and cytotoxic effect were assessed in TNBC cells, patient-derived CAFs, and patient-derived organoids (PDOs). In vivo efficacy was evaluated in the murine orthotopic TNBC 4T1 allograft model, assessing tumor growth inhibition, toxicity, CAFs depletion, extracellular matrix degradation, apoptosis induction, and TME-associated cellular and stromal changes. NP-FAP-DOX exhibited controlled drug release, selective binding to FAP-α, and cytotoxicity in TNBC cells, patient-derived CAFs, and PDOs. In vivo, NP-FAP-DOX reduced tumor growth, depleted CAFs, degraded the extracellular matrix, induced apoptosis, increased lymphocyte infiltration, and decreased M2-like macrophages. Compared with free doxorubicin, NP-FAP-DOX enhanced therapeutic efficacy while reducing cardiotoxicity and systemic side effects. These findings highlight NP-FAP-DOX as a promising nanomedicine strategy for TNBC, integrating tumor inhibition, TME remodeling, and immune activation, with strong potential for clinical translation.

Autor:innen und Institutionen

  • Biomedical Research Institute INCLIVA, Breast Cancer Biology Research Group, Valencia, Spain.
  • Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
  • Unidad Mixta de Investigación en Nanomedicina y Sensores. Universitat Politècnica de València, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain.
  • CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, Valencia, Spain.
  • Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • CIBER de Oncología (CIBERONC), Instituto de Salud Carlos III, Valencia, Spain.

ORCID-Profile: Iris Garrido-Cano

Förderung

  • Instituto de Salud Carlos III
  • Ministerio de Ciencia e Innovación
  • Universitat Politècnica de València
  • Generalitat Valenciana
  • Fundación Científica Asociación Española Contra el Cáncer
  • Ministerio de Universidades
  • Sociedad Española de Oncología Médica

Zitieren

APA

Lameirinhas, A., Díez, P., Hicke, F. J., Ágreda-Roca, A., Torres-Ruiz, S., Sánchez-Serrano, P., Tapia, M., Lluch, A., Bermejo, B., Cejalvo, J. M., Martínez-Máñez, R., Eroles, P., & Garrido-Cano, I. (2026). Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer. Biomaterials Research, 30. https://doi.org/10.34133/bmr.0347

Vancouver

Lameirinhas A, Díez P, Hicke FJ, Ágreda-Roca A, Torres-Ruiz S, Sánchez-Serrano P, et al. Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer. Biomaterials Research. 2026;30. doi:10.34133/bmr.0347

BibTeX
@article{Lameirinhas2026,
  author = {Lameirinhas, Ana and Díez, Paula and Hicke, Francisco J and Ágreda-Roca, Anna and Torres-Ruiz, Sandra and Sánchez-Serrano, Paloma and Tapia, Marta and Lluch, Ana and Bermejo, Begoña and Cejalvo, Juan Miguel and Martínez-Máñez, Ramón and Eroles, Pilar and Garrido-Cano, Iris},
  title = {Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer},
  journal = {Biomaterials Research},
  year = {2026},
  volume = {30},
  doi = {10.34133/bmr.0347}
}
Kostenlos starten →